Connie Westhoff, SBB, PhD
Member, Lab Head
The primary focus of the laboratory is to improve transfusion practice through the use of genomics to bring personalized medicine to the field with a focus on patients with Sickle Cell Disease (SCD). The discovery that patients with SCD have increase RH genetic diversity has led to our current studies to address alloimmunization by implementing genetic matching.
A second focus is on the production of cultured RBCs (cRBCs) from stem and iPS cells, which hold the promise of revolutionizing the existing RBC supply system, however the number of cells and the cost of production remain major road blocks. Our goal is to generate clinically useful rare reagent cRBCs to improve and expedite patient workups. This lays the foundation for the future by providing clinically useful products that require relatively small amounts achievable with today’s technology.
Phone: +1 (212) 570-3205
Blood Group Genomics
Doris Duke Foundation Innovations in Clinical Research Award. Expanding Genomic Approaches for Transfusion Therapy for Patients with Sickle Cell Disease
R01 HL130764-01 NHLBI/NIH Clinical Grade Cultured Rare Red Blood Cells as Reagents and Future Transfusion Support